SABR + HDR: One SABR treatment + one HDR brachytherapy treatment
Study summary
Favorable-risk prostate cancer represent a large proportion of patients diagnosed with prostate cancer and image guided radiation therapy (IGRT) is commonly used to treat these patients using protracted courses of up to 39 treatments over 8 weeks. Stereotactic ablative body radiotherapy (SABR) protocols hold the promise of more convenience, less side effects, less cost and improved system capacity without sacrificing excellent cancer control rates. By the same token, prostate high-dose rate (HDR) brachytherapy boost has been shown to be superior to standard external beam radiation. While two HDR fractions appear to optimize patient convenience and outcomes while minimizing costs, we wanted to determine the tolerability of combining one MR-guided HDR treatment with one SABR treatment to further reduce HDR resource use while maintaining favourable treatment outcomes.
Eligibility
Sex
MALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Histologically confirmed diagnosis of adenocarcinoma of the prostate
* Favorable risk disease defined as either:
* Low risk disease: T1-T2c, grade group 1, PSA \< 10 ng/ml or
* Favorable intermediate risk disease: One of T2c, grade group 2, or PSA 10-20 ng/ml. Patients cannot have percent core positivity \> 50%
* Prostate volume \< 60 cc as determined by US, CT or MRI
* Ability to undergo MR imaging
* Provide written informed consent
Exclusion Criteria:
* Documented nodal or distant metastases
* Previous pelvic radiotherapy
* Previous transurethral resection of prostate, previous prostatectomy or HIFU
* Use of androgen deprivation therapy. Use of 5-alpha-reductase inhibitors permitted
* Poor baseline urinary function defined as International Prostate Symptom Score (IPSS) \>15
* Contra-indication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
* Significant medical co-morbidity rendering patient unsuitable for general anaesthesia
Primary outcome measure(s)
Acute Toxicities — 6 months Acute GU and GI toxicities according to the NCI CTCAE v4.0
Trial sites (1)
Facility
City
Region
Status
Sunnybrook Health Sciences Centre
Toronto
Ontario
Recruiting
More Sunnybrook Health Sciences Centre trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
